211 related articles for article (PubMed ID: 32185725)
1. Small Molecular Immune Modulators as Anticancer Agents.
Han Y; Zhu L; Wu W; Zhang H; Hu W; Dai L; Yang Y
Adv Exp Med Biol; 2020; 1248():547-618. PubMed ID: 32185725
[TBL] [Abstract][Full Text] [Related]
2. The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves.
Kerr WG; Chisholm JD
J Immunol; 2019 Jan; 202(1):11-19. PubMed ID: 30587569
[TBL] [Abstract][Full Text] [Related]
3. Current status of immunotherapy.
Suzuki S; Ishida T; Yoshikawa K; Ueda R
Jpn J Clin Oncol; 2016 Mar; 46(3):191-203. PubMed ID: 26819277
[TBL] [Abstract][Full Text] [Related]
4. Big opportunities for small molecules in immuno-oncology.
Adams JL; Smothers J; Srinivasan R; Hoos A
Nat Rev Drug Discov; 2015 Sep; 14(9):603-22. PubMed ID: 26228631
[TBL] [Abstract][Full Text] [Related]
5. Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Melero I; Berman DM; Aznar MA; Korman AJ; Pérez Gracia JL; Haanen J
Nat Rev Cancer; 2015 Aug; 15(8):457-72. PubMed ID: 26205340
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint inhibitors in immunotherapy of ovarian cancer.
Wang DH; Guo L; Wu XH
Tumour Biol; 2015 Jan; 36(1):33-9. PubMed ID: 25409618
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial Cancer Immunotherapies.
Hellmann MD; Friedman CF; Wolchok JD
Adv Immunol; 2016; 130():251-77. PubMed ID: 26923003
[TBL] [Abstract][Full Text] [Related]
10. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.
Shahabi V; Postow MA; Tuck D; Wolchok JD
Am J Clin Oncol; 2015 Feb; 38(1):90-7. PubMed ID: 25616204
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors.
Haanen JB; Robert C
Prog Tumor Res; 2015; 42():55-66. PubMed ID: 26382943
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy.
Lee L; Gupta M; Sahasranaman S
J Clin Pharmacol; 2016 Feb; 56(2):157-69. PubMed ID: 26183909
[TBL] [Abstract][Full Text] [Related]
13. Emerging Opportunities and Challenges in Cancer Immunotherapy.
Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives.
Atkins MB; Larkin J
J Natl Cancer Inst; 2016 Jun; 108(6):djv414. PubMed ID: 26839346
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapy and Immunosuppression in the Tumor Microenvironment.
Allegrezza MJ; Conejo-Garcia JR
Trends Cancer; 2017 Jan; 3(1):19-27. PubMed ID: 28718424
[TBL] [Abstract][Full Text] [Related]
16. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
17. Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response.
Francis A; Venkatesh GH; Zaarour RF; Zeinelabdin NA; Nawafleh HH; Prasad P; Buart S; Terry S; Chouaib S
Crit Rev Immunol; 2018; 38(6):505-524. PubMed ID: 31002604
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in cancer immunology and immunology-based anticancer therapies.
Kumar S; Saini RV; Mahindroo N
Biomed Pharmacother; 2017 Dec; 96():1491-1500. PubMed ID: 29198747
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales.
Fan L; Li Y; Chen JY; Zheng YF; Xu XM
Cancer Lett; 2019 Aug; 456():23-28. PubMed ID: 30959079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
